Since 1995, with the availability of cryopreserved amniotic membrane (AM), the use of AM
as a patch or graft for ocular surface reconstruction has become recognized as an important
alternative for treatment of persistent epithelial defects and sterile ulceration that are
refractory to conventional therapy. A major problem with evaluating the efficacy of AM
transplantation is the lack of controlled clinical studies. Moreover, for some diseases there is
no accepted “standard” therapy, and the incidence of the disease is too low to allow proper …